Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intravenous ferric carboxymaltose in renal transplant recipients with iron-deficiency anemia
2012-003915-73Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric carboxymaltose in iron deficiency anemia (IDA) and chronic kidney disease (CKD), sponsored by Medical University of Vienna. Primary endpoint: Change in gene expression in lymphocytes. Started Aug 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-003915-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003915-73.